EA199900057A1 - MATRIX METALLOPROTEINASE INHIBITORS - Google Patents

MATRIX METALLOPROTEINASE INHIBITORS

Info

Publication number
EA199900057A1
EA199900057A1 EA199900057A EA199900057A EA199900057A1 EA 199900057 A1 EA199900057 A1 EA 199900057A1 EA 199900057 A EA199900057 A EA 199900057A EA 199900057 A EA199900057 A EA 199900057A EA 199900057 A1 EA199900057 A1 EA 199900057A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mmp
tnf
alpha
matrix metalloproteinase
metalloproteinase inhibitors
Prior art date
Application number
EA199900057A
Other languages
Russian (ru)
Other versions
EA001432B1 (en
Inventor
Марко Альпеджани
Франческа Абрате
Пьерлуиджи Биссолино
Массимилиано Палладино
Этторе Перроне
Original Assignee
Фармация Энд Апджон С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Энд Апджон С.П.А. filed Critical Фармация Энд Апджон С.П.А.
Publication of EA199900057A1 publication Critical patent/EA199900057A1/en
Publication of EA001432B1 publication Critical patent/EA001432B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

Производные сукцинамида формулы (I), в которых W обозначает группу -COH или -CONHOH, каждый R, Rи Rобозначает водород или органический остаток, Rобозначает остаток альфа-аминокислоты и Rобозначает органическую группу, являются ингибиторами матриксных металлопротеиназ (ММР) и высвобождения из клеток фактора-альфа некроза опухолей (TNF), поэтому их можно эффективно использовать для профилактики и лечения болезней, вызываемых ММР или TNF. Данное изобретение относится также к способу получения указанных соединений и к содержащим их фармацевтическим композициям.Международная заявка была опубликована вместе с отчетом о международном поиске.The succinamide derivatives of formula (I) in which W stands for the group —COH or —CONHOH, each R, R and R represents hydrogen or organic residue, R represents an alpha-amino acid residue and R denotes an organic group, are inhibitors of matrix metalloproteinases (MMP) and release from factor -alpha necrosis of tumors (TNF), so they can be effectively used for the prevention and treatment of diseases caused by MMP or TNF. The invention also relates to a method for producing said compounds and pharmaceutical compositions containing them. The international application was published together with an international search report.

EA199900057A 1996-06-27 1997-06-20 Matrix metalloproteinase inhibitors EA001432B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9613547.0A GB9613547D0 (en) 1996-06-27 1996-06-27 Matrix metalloproteinase inhibitors
PCT/EP1997/003251 WO1997049674A1 (en) 1996-06-27 1997-06-20 Matrix metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
EA199900057A1 true EA199900057A1 (en) 1999-06-24
EA001432B1 EA001432B1 (en) 2001-02-26

Family

ID=10796022

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900057A EA001432B1 (en) 1996-06-27 1997-06-20 Matrix metalloproteinase inhibitors

Country Status (18)

Country Link
EP (1) EP0920414A1 (en)
JP (1) JP2000514043A (en)
KR (1) KR20000022534A (en)
AR (1) AR008621A1 (en)
AU (1) AU733938B2 (en)
BR (1) BR9709902A (en)
CA (1) CA2257404A1 (en)
CZ (1) CZ430398A3 (en)
EA (1) EA001432B1 (en)
GB (1) GB9613547D0 (en)
ID (1) ID17792A (en)
IL (1) IL127262A0 (en)
NO (1) NO986049L (en)
NZ (1) NZ333550A (en)
PL (1) PL330897A1 (en)
TW (1) TW460441B (en)
WO (1) WO1997049674A1 (en)
ZA (1) ZA975631B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19719817A1 (en) * 1997-05-13 1998-11-19 Hoechst Ag Substituted 6- and 7-aminotetrahydroisoquinoline carboxylic acids
JP2001513484A (en) * 1997-07-31 2001-09-04 ザ プロクター アンド ギャンブル カンパニー Acyclic metalloprotease inhibitors
GB9803005D0 (en) 1998-02-12 1998-04-08 British Biotech Pharm Anti-inflammatory agents
GB9804777D0 (en) * 1998-03-07 1998-04-29 British Biotech Pharm Anti-inflammatory agents
US6335324B1 (en) 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
GB9901863D0 (en) 1999-01-29 1999-03-17 British Biotech Pharm Antibacterial agents
HUP0202199A2 (en) 1999-03-03 2002-10-28 Procter & Gamble Alkenyl- and alkynyl-containing metalloprotease inhibitors
AU2268401A (en) * 1999-12-17 2001-06-25 Versicor Inc Novel succinate compounds, compositions and methods of use and preparation
GB9930754D0 (en) * 1999-12-29 2000-02-16 Smithkline Beecham Plc Novel compounds
AU2001271068A1 (en) * 2000-07-18 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
ATE360014T1 (en) 2001-06-15 2007-05-15 Vicuron Pharm Inc BICYCLIC PYRROLIDINE COMPOUNDS
AR036053A1 (en) 2001-06-15 2004-08-04 Versicor Inc N-FORMIL-HYDROXYLAMINE COMPOUNDS, A PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
US20110230479A1 (en) * 2005-04-15 2011-09-22 Longo Frank M Neurotrophin mimetics and uses thereof
KR20060116552A (en) * 2005-05-10 2006-11-15 연세대학교 산학협력단 N-formyl hydroxylamine derivatives as matrix metalloproteinase inhibitors
FR2949463B1 (en) * 2009-08-26 2011-09-16 Commissariat Energie Atomique MMP INHIBITORS
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
CA3125909C (en) 2009-11-12 2023-10-31 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
BR112021006407A8 (en) 2018-10-04 2022-12-06 Inst Nat Sante Rech Med use of egfr inhibitors for keratoderms

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DK77487A (en) * 1986-03-11 1987-09-12 Hoffmann La Roche hydroxylamine
DE69108529T2 (en) * 1990-12-03 1995-11-30 Celltech Therapeutics Ltd Peptidyl derivatives.
CA2058797A1 (en) * 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
EP0520573A1 (en) * 1991-06-27 1992-12-30 Glaxo Inc. Cyclic imide derivatives

Also Published As

Publication number Publication date
CZ430398A3 (en) 1999-08-11
EA001432B1 (en) 2001-02-26
AR008621A1 (en) 2000-02-09
PL330897A1 (en) 1999-06-07
NO986049D0 (en) 1998-12-22
GB9613547D0 (en) 1996-08-28
NO986049L (en) 1999-03-01
KR20000022534A (en) 2000-04-25
ZA975631B (en) 1998-01-30
TW460441B (en) 2001-10-21
BR9709902A (en) 1999-08-10
CA2257404A1 (en) 1997-12-31
WO1997049674A1 (en) 1997-12-31
AU3342297A (en) 1998-01-14
EP0920414A1 (en) 1999-06-09
IL127262A0 (en) 1999-09-22
AU733938B2 (en) 2001-05-31
ID17792A (en) 1998-01-29
NZ333550A (en) 2000-07-28
JP2000514043A (en) 2000-10-24

Similar Documents

Publication Publication Date Title
EA199900057A1 (en) MATRIX METALLOPROTEINASE INHIBITORS
EA200101085A1 (en) HYDROXAMIC ACIDS, DERIVATIVES OF AROMATIC SULPHONES, - METALLOPROTEASIS INHIBITORS
BR9810841A (en) Alicyclic metalloprotease inhibitors
DOP2004001052A (en) 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1 INHIBITORS AMINO
EA200000871A1 (en) PHOSPHOLIPASE ENZYME INHIBITORS
EA200400480A1 (en) N-SUBSTITUTED PYRROLIDINE DERIVATIVES AS DIPEPTIDYLPEPIDASE INHIBITORS
EA200100804A1 (en) SULPHOOROMATIC DERIVATIVES OF HYDROXAMIC ACID AS METHYPE PROTEASIS INHIBITORS
DK0783486T3 (en) Newly Prostaglandin Synthase Inhibitors
EA200301216A1 (en) MULTICYCLIC HETEROARYLS SUBSTITUTED WITH QUINUCLIDINES FOR THE DISEASE TREATMENT
ID18143A (en) RESISTANT OF METALOPROTEASE AMINA OF SUBSTITUTED CYCLE
NO963499L (en) Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
EA200100971A1 (en) NEW COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS
ES2185307T3 (en) FARNESIL TRANSFERASA INHIBITORS THAT HAVE A PIPERIDINIC STRUCTURE AND PROCEDURE FOR THEIR PREPARATION.
NO20024521L (en) Heterocyclic side chain-containing metalloprotease inhibitors
CY1109328T1 (en) THIENODIBENZOAZULENIUM COMPOUNDS AS TUMOR NECROSION FACTOR INHIBITORS
BR9713178A (en) Spirocyclic metalloprotease inhibitors.
NO991674D0 (en) Interleukin-1 <beta> converting enzyme inhibitor sulfonamides
BR9712792A (en) Bidentate metalloprotease inhibitors.
EA200400708A1 (en) INHIBITORS 11-BETA-HYDROXYSTEROID DEGYDROGENASE TYPE 1
TR200003252T2 (en) Interleukin-1ß converting enzyme succinamide inhibitors.
BR0109328A (en) Unsubstituted metalloprotease inhibitors containing heterocyclic side chain
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
DE69702182T2 (en) ALKYLATED STYROLE AS PRODRUGS TO COX-2 INHIBITORS
BR0109348A (en) Unsubstituted metalloprotease inhibitors which contain carbocyclic side chains
ATE198323T1 (en) DIPHENYLSTIBENES AS PRODRUGS TO COX-2 INHIBITORS

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU